Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Akebia Therapeutics (AKBA) Gross Margin (2018 - 2026)

Akebia Therapeutics has reported Gross Margin over the past 7 years, most recently at 78.25% for Q4 2025.

  • Quarterly Gross Margin fell 5547.0% to 78.25% in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 83.29% through Dec 2025, down 1102.0% year-over-year, with the annual reading at 83.29% for FY2025, 23.0% up from the prior year.
  • Gross Margin was 78.25% for Q4 2025 at Akebia Therapeutics, down from 84.03% in the prior quarter.
  • Over five years, Gross Margin peaked at 133.72% in Q4 2024 and troughed at 0.79% in Q2 2021.
  • The 5-year median for Gross Margin is 79.92% (2024), against an average of 74.41%.
  • Year-over-year, Gross Margin skyrocketed 19035bps in 2021 and then tumbled -5547bps in 2025.
  • A 5-year view of Gross Margin shows it stood at 107.62% in 2021, then crashed by -46bps to 57.69% in 2022, then surged by 127bps to 130.92% in 2023, then rose by 2bps to 133.72% in 2024, then tumbled by -41bps to 78.25% in 2025.
  • Per Business Quant, the three most recent readings for AKBA's Gross Margin are 78.25% (Q4 2025), 84.03% (Q3 2025), and 84.12% (Q2 2025).